サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1782020

リキッドバイオプシー市場：サンプルタイプ別、バイオマーカー別、技術別、製品別、臨床応用別、用途別、エンドユーザー別、国別、地域別：世界産業分析、市場規模、市場シェア、2025年～2032年予測

Liquid Biopsy Market, By Sample Type, By Biomarker, By Technology, By Product, By Clinical Application, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 383 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
リキッドバイオプシー市場：サンプルタイプ別、バイオマーカー別、技術別、製品別、臨床応用別、用途別、エンドユーザー別、国別、地域別：世界産業分析、市場規模、市場シェア、2025年～2032年予測
出版日: 2025年07月21日
発行: AnalystView Market Insights
ページ情報: 英文 383 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

リキッドバイオプシー市場規模は2024年に121億2,424万米ドルとなり、2025年から2032年にかけてCAGR 11.6％で拡大

リキッドバイオプシー市場-市場力学

がんの有病率の増加は、早期スクリーニングと治療薬の需要を押し上げ、市場成長を促進すると予想されます。

がんが世界的に罹患率と死亡率の主な要因として浮上するにつれ、ヘルスケアシステムは悪性腫瘍を進行前に発見するための早期診断をますます優先するようになっています。このシフトは、リキッドバイオプシー、画像技術、分子診断評価などの高度なスクリーニング技術の利用を促進しています。米国国立がん研究所は、2025年までに米国で約204万1910人のがん患者が新たに確認され、61万8120人ががんで死亡すると予測しています。その結果、早期診断から治療まで、がん治療の一連の流れは、増大する医療需要に対応するために急速に進化しており、早期スクリーニング機器と画期的な治療薬の両方の市場をさらに刺激しています。さらに、ゲノム技術や分子技術の進歩も市場に成長機会をもたらす可能性があります。とはいえ、標準化の欠如と規制上のハードルが市場拡大を阻害する可能性もあります。

リキッドバイオプシー市場-主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025年～2032年）に約11.6％のCAGRで毎年成長すると予測されています。

サンプルタイプのセグメンテーションに基づくと、血液サンプルは2024年に最大の市場シェアを示すと予測されました。

バイオマーカーセグメンテーションに基づくと、2024年には循環腫瘍細胞（CTC）が主要用途でした。

技術セグメンテーションに基づくと、2024年には多遺伝子並列解析（NGS）が主要技術でした。

製品セグメント別では、2024年の主要製品は装置でした。

臨床応用のセグメンテーションに基づくと、2024年の主要エンドユーザーは治療法の選択でした。

用途別では、2024年のエンドユーザーはがんがトップ

エンドユーザー別では、病院と研究所が2024年の主要エンドユーザーでした。

地域別では、北米が2024年に収益を生み出す主要市場です。

リキッドバイオプシー市場-セグメンテーション分析：

世界のリキッドバイオプシー市場は、サンプルタイプ、用途、技術、製品、臨床応用、アプリケーション、エンドユーザー、地域に基づいてセグメント化されます。

市場はサンプルタイプによって3つのセグメントに分類される。血液サンプルとその他。血液サンプルは市場成長の主な促進要因です。血液サンプルは、主に採取の容易さ、低侵襲性、患者のコンプライアンスレベルの高さにより、リキッドバイオプシー分野を支配しています。血液ベースのリキッドバイオプシーは、循環腫瘍DNA（ctDNA）、循環腫瘍細胞（CTC）、その他のさまざまなバイオマーカーの検出と分析を容易にし、腫瘍の遺伝子プロファイルの完全な概要をリアルタイムで提供します。組織生検と比較して、血液サンプルは、がんの診断、予後、治療モニタリング、早期発見に、より迅速で安全かつ経済的な選択肢を提供します。病院、診断センター、研究機関が血液ベースの検査を広く採用していることが、市場での主導的地位をさらに強化しています。

市場はバイオマーカーに基づいて3つのセグメントに分類される。循環腫瘍細胞（CTC）、循環腫瘍DNA（ctDNA）、細胞外ビークル（EV）などです。循環腫瘍細胞（CTC）は市場の成長をリードしています。CTCは、がんの診断、予後、治療モニタリングにおいて重要な役割を果たすため、リキッドバイオプシー市場の成長促進要因となっています。CTCは原発性腫瘍や転移性腫瘍から分離して血流にのって移動するがん細胞であり、腫瘍の不均一性や転移の可能性についての本質的な洞察を提供します。侵襲的な処置を必要とせず、疾患の進行や治療反応に関するデータをリアルタイムで提供できることから、腫瘍学において好ましいバイオマーカーとされています。

市場は技術によって2つのセグメントに分類される。多遺伝子並列解析（NGS）と単一遺伝子解析（PCRマイクロアレイ）です。多遺伝子並列解析（NGS）は市場成長の主な促進要因です。次世代シーケンサー（NGS）を利用した多遺伝子並列解析は、卓越した感度と特異性で複数の遺伝子変化を同時に評価できるため、リキッドバイオプシー市場の成長につながります。NGSは、少量のサンプルからの広範なゲノムプロファイリングを容易にし、腫瘍生物学、変異負荷、可能性のある治療標的に関する詳細な洞察を臨床医に提供します。この手法は、稀な突然変異や耐性メカニズムをリアルタイムで同定できるため、個別化医療に特に有益です。がんの早期発見、治療法の選択、微小残存病変のモニタリングのために、がん領域でNGSベースのリキッドバイオプシー・パネルの導入が増加していることが、市場の成長を大きく後押ししています。

市場は製品によって3つのカテゴリーに区分される。機器、消耗品キットと試薬、ソフトウェアとサービスです。市場の成長をリードするのは機器です。循環腫瘍細胞（CTC）、循環腫瘍DNA（ctDNA）、エクソソームなどの循環バイオマーカーを正確に同定・分析できる高度な技術に対する需要の高まりに後押しされ、リキッドバイオプシー市場拡大の最前線にあるのは機器です。NGSプラットフォーム、PCRシステム、マイクロ流体デバイス、自動リキッドハンドリングシステムを含むこれらの機器は、診断プロセスにおいて高スループット、高感度、高精度を達成するために不可欠です。腫瘍学アプリケーション用に設計された、革新的で使い勝手の良い統合システムの進歩が続いているため、病院、診断研究所、研究機関での採用が加速しています。

市場は、臨床応用に基づいて4つのセグメントに分類される。治療選択、治療モニタリング、早期がんスクリーニング、再発モニタリング、その他です。治療法の選択は市場成長の主な促進要因です。循環腫瘍DNA（ctDNA）またはその他のバイオマーカーを調べることにより、リキッドバイオプシーは侵襲的な組織採取を必要とせずに、特定の変異、遺伝子融合、耐性メカニズムの検出を容易にします。この方法によって、がん専門医は、標的治療や免疫療法などの治療を患者の明確な分子プロファイルに従ってカスタマイズすることができ、それによって臨床転帰を向上させ、不必要な毒性を減らすことができます。精密医療への注目の高まりと、治療中の腫瘍の動的変化を追跡するリキッドバイオプシーの能力が相まって、さまざまながん種における治療法の選択においてリキッドバイオプシーが果たす重要な役割がさらに強化されています。

市場は用途別に8つのセグメントに分類される。がん、生殖医療、肺がん、前立腺がん、乳がん、大腸がん、白血病、消化器がん、その他です。がん分野は市場成長の最前線にあります。リキッドバイオプシー分野では、様々ながんの世界的有病率の増加と非侵襲的診断法に対する需要の高まりに後押しされ、がん分野が市場拡大を牽引しています。リキッドバイオプシーは、体液（主に血液）由来のctDNA、CTC、エクソソームなどのバイオマーカーを調べることで、がんの早期発見、腫瘍プロファイリング、治療モニタリング、再発予測のための画期的な方法を提供します。従来の組織生検に比べ、リスクの低減、迅速な納期、腫瘍の不均一性を捉える能力などの利点があるため、腫瘍学において不可欠な機器として確立しています。精密医療ががん治療に不可欠になるにつれて、肺がん、乳がん、大腸がん、前立腺がんなどの固形がんの管理におけるリキッドバイオプシーの応用は継続的に拡大しており、この分野の進歩をさらに後押ししています。

市場はエンドユーザー別に、病院・研究所、専門クリニック、学術・研究センター、その他の4つのセグメントに分類されます。病院・研究所セグメントは市場成長の最前線にあります。このセグメントは、高度な診断技術の採用が増加し、これらの環境で実施されるがんスクリーニングやモニタリングの数が増加しているため、リキッドバイオプシー産業の拡大を牽引しています。病院や臨床検査室は、診断評価を受ける患者の最初の接点となることが多く、リキッドバイオプシー検査の展開に不可欠なセンターとなっています。これらの施設は、熟練した専門家の存在、確立されたインフラ、NGSやPCRプラットフォームのような高スループット機器へのアクセスから利点を得ています。

リキッドバイオプシー市場-地理的洞察

北米が市場成長でリードしているのは、堅調な研究開発と堅実な償還の枠組みによるものです。この地域の洗練されたヘルスケアシステム、早期がん検診に関する意識の高まり、学術機関と業界利害関係者の強力なパートナーシップは、北米が世界のリキッドバイオプシー市場で果たす役割をさらに強固なものにしています。米国医師会の報告によると、米国は2023年にヘルスケアに4兆8,665億米ドルを割り当てています。欧州もまた、がんに対する意識の高まり、ヘルスケアへのアクセスの強化、早期発見イニシアチブに対する政府の資金援助に支えられ、市場のかなりの部分を占めています。

リキッドバイオプシー市場-競合情勢：

リキッドバイオプシー市場は激しい競争と絶え間ない進化を特徴としており、多数の既存企業や新規参入企業が技術革新、提携、成長戦略を通じて競争上の優位性を確保しようとしています。各社は、リキッドバイオプシーアッセイの感度、特異性、スピードを向上させるため、次世代シーケンシング（NGS）、液滴デジタルPCR、多遺伝子パネル検査などの最先端技術に基づいて競争しています。主要企業は、アジア太平洋やラテンアメリカの新興市場に重点を置き、未開拓の機会を捉えるために地域子会社や販売網を設立しています。

目次

第1章 リキッドバイオプシー市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 リキッドバイオプシーの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 リキッドバイオプシー産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 リキッドバイオプシー市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 リキッドバイオプシー市場情勢

  • リキッドバイオプシー市場シェア分析、2024年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 リキッドバイオプシー市場- サンプルタイプ別

  • 概要
    • サンプルタイプ別セグメントシェア分析
    • 血液サンプル
    • その他

第8章 リキッドバイオプシー市場- バイオマーカー別

  • 概要
    • バイオマーカー別セグメントシェア分析
    • 循環腫瘍細胞（CTC）
    • 循環腫瘍DNA（ctDNA）
    • 細胞外車両（EV）
    • その他

第9章 リキッドバイオプシー市場- 技術別

  • 概要
    • 技術別セグメントシェア分析
    • マルチ遺伝子並列解析（NGS）
    • 単一遺伝子解析（PCRマイクロアレイ）

第10章 リキッドバイオプシー市場- 製品別

  • 概要
    • 製品別セグメントシェア分析
    • 機器
    • 消耗品キットおよび試薬
    • ソフトウェアとサービス

第11章 リキッドバイオプシー市場- 臨床用途別

  • 概要
    • 臨床応用別セグメントシェア分析
    • 治療法の選択
    • 治療モニタリング
    • 早期がん検診
    • 再発モニタリング
    • その他

第12章 リキッドバイオプシー市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • がん
    • 生殖保健
    • 肺がん
    • 前立腺がん
    • 乳がん
    • 大腸がん
    • 白血病
    • 消化器がん
    • その他

第13章 リキッドバイオプシー市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院と研究所
    • 専門クリニック
    • 学術研究センター
    • その他

第14章 リキッドバイオプシー市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第15章 主要ベンダー分析- リキッドバイオプシー業界

  • 競合ダッシュボード
    • Competitive Benchmarking
    • Competitive Positioning
  • 企業プロファイル
    • Guardant Health, Inc.
    • Foundation Medicine, Inc.（Roche subsidiary）
    • Illumina, Inc.
    • GRAIL, Inc.（subsidiary of Illumina）
    • Bio-Rad Laboratories, Inc.
    • Exact Sciences Corporation
    • Thermo Fisher Scientific Inc.
    • Natera, Inc.
    • Freenome Holdings, Inc.
    • QIAGEN NV
    • Lucence Diagnostics
    • Inivata Ltd.（NeoGenomics subsidiary）
    • Angle plc
    • Sysmex Corporation
    • Biocept, Inc.
    • Oncocyte Corporation
    • Personal Genome Diagnostics（PGDx）
    • Chronix Biomedical
    • Epic Sciences, Inc.
    • Cynvenio Biosystems, Inc.
    • Others

第16章 アナリストの全方位展望

目次
Product Code: ANV5421

REPORT HIGHLIGHT

Liquid Biopsy Market size was valued at US$ 12,124.24 Million in 2024, expanding at a CAGR of 11.6% from 2025 to 2032.

A liquid biopsy is a non-invasive diagnostic procedure that evaluates bodily fluids, mainly blood, to identify cancer or other illnesses. It analyzes biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) to detect genetic or molecular alterations linked to a tumor. Liquid biopsies can facilitate early cancer detection, monitor the effectiveness of treatments, and evaluate tumor progression. Much of the initial research on liquid biopsies has focused on lung, breast, and prostate cancers; however, this technology is anticipated to influence all cancer types. Liquid biopsy represents a relatively recent testing method with numerous potential revolutionary applications in cancer therapy, including several uses that have received approval from the U.S. Food and Drug Administration (FDA). Ongoing research continues to explore its advantages.

Liquid Biopsy Market- Market Dynamics

The increasing prevalence of cancer is anticipated to boost the demand for early screening and therapeutics, thereby driving market growth.

As cancer emerges as a primary contributor to morbidity and mortality globally, healthcare systems are increasingly prioritizing early-stage diagnostics to detect malignancies before their advancement. This shift is propelling the utilization of sophisticated screening technologies, including liquid biopsies, imaging techniques, and molecular diagnostic assessments. The National Cancer Institute projects that by 2025, approximately 2,041,910 new cancer cases will be identified in the United States, with 618,120 fatalities attributed to the disease. Consequently, the cancer care continuum, encompassing early diagnosis through to treatment, is rapidly evolving to address the escalating healthcare demands, thereby further stimulating the market for both early screening instruments and groundbreaking therapeutics. Additionally, advancements in genomic and molecular technologies may present growth opportunities for the market. Nevertheless, the lack of standardization and regulatory hurdles could impede market expansion.

Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.6% over the forecast period (2025-2032)

Based on the Sample Type segmentation, the Blood Sample was predicted to show maximum market share in the year 2024

Based on Biomarker segmentation, Circulating Tumor Cells (CTCs) were the leading application in 2024

Based on Technology segmentation, Multi-gene-parallel Analysis (NGS) was the leading Technology in 2024

Based on Product segmentation, Instruments were the leading Product in 2024

Based on Clinical application segmentation, Therapy Selection was the leading End-User in 2024

Based on Application segmentation, Cancer was the leading End-User in 2024

Based on End-User segmentation, Hospitals and Laboratories were the leading End-User in 2024

Based on region, North America was the leading revenue generator in 2024

Liquid Biopsy Market- Segmentation Analysis:

The Global Liquid Biopsy Market is segmented based on Sample Type, Application, Technology, Product, Clinical Application, Application, End-User, and Region.

The market is categorized into three segments according to Sample Type: Blood Sample and Others. Blood Sample is the primary driver of market growth. Blood samples dominate the Liquid Biopsy sector, mainly due to their ease of collection, low invasiveness, and high levels of patient compliance. Blood-based liquid biopsies facilitate the detection and analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various other biomarkers, providing a thorough overview of the tumor's genetic profile in real-time. In comparison to tissue biopsies, blood samples offer a quicker, safer, and more economical option for cancer diagnosis, prognosis, treatment monitoring, and early detection. The extensive adoption of blood-based tests by hospitals, diagnostic centers, and research institutions further reinforces their leading position in the market.

The market is categorized into three segments based on biomarkers: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), and Extracellular Vehicles (EVs), among others. Circulating Tumor Cells (CTCs) lead the growth of the market. CTCs are the primary drivers of growth in the Liquid Biopsy market, due to their significant role in cancer diagnosis, prognosis, and treatment monitoring. CTCs are cancer cells that separate from primary or metastatic tumors and travel through the bloodstream, providing essential insights into tumor heterogeneity and metastatic potential. Their capacity to deliver real-time data on disease progression and treatment response without requiring invasive procedures renders them a preferred biomarker in oncology.

The market is categorized into two segments based on technology: Multi-gene-parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays). Multi-gene-parallel Analysis (NGS) is the primary driver of market growth. The multi-gene parallel analysis utilising Next-Generation Sequencing (NGS) leads to the growth of the Liquid Biopsy market, owing to its capability to concurrently assess multiple genetic alterations with exceptional sensitivity and specificity. NGS facilitates extensive genomic profiling from small sample volumes, equipping clinicians with in-depth insights into tumor biology, mutation load, and possible therapeutic targets. This methodology is particularly beneficial for personalized medicine, as it enables the identification of rare mutations and resistance mechanisms in real time. The rising implementation of NGS-based liquid biopsy panels in oncology for early cancer detection, treatment selection, and monitoring of minimal residual disease is greatly enhancing the market's growth.

The market is segmented into three categories based on Product: Instruments, Consumables Kits and Reagents, and Software and Services. Instruments lead the growth of the market. Instruments are at the forefront of the Liquid Biopsy market expansion, propelled by the rising demand for sophisticated technologies that can accurately identify and analyze circulating biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. These instruments, which include NGS platforms, PCR systems, microfluidic devices, and automated liquid handling systems, are crucial for achieving high throughput, sensitivity, and precision in diagnostic processes. The ongoing advancement of innovative, user-friendly, and integrated systems designed for oncology applications has accelerated their adoption in hospitals, diagnostic laboratories, and research institutions.

The market is categorized into four segments based on Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, and Others. Therapy Selection is the primary driver of market growth. By examining circulating tumor DNA (ctDNA) or other biomarkers, liquid biopsy facilitates the detection of specific mutations, gene fusions, and resistance mechanisms without requiring invasive tissue sampling. This method enables oncologists to customize therapies such as targeted treatments or immunotherapies according to a patient's distinct molecular profile, thereby enhancing clinical outcomes and reducing unnecessary toxicity. The increasing focus on precision medicine, coupled with the capability of liquid biopsy to track dynamic tumor alterations during treatment, further reinforces its essential role in therapy selection across different cancer types.

The market is categorized into eight segments based on application: Cancer, Reproductive Health, Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Gastrointestinal Cancer, and Others. The cancer segment is at the forefront of market growth. In the Liquid Biopsy sector, the cancer segment is driving market expansion, propelled by the increasing global prevalence of various cancers and the rising demand for non-invasive diagnostic methods. Liquid biopsy provides a revolutionary method for the early detection of cancer, tumor profiling, treatment monitoring, and predicting relapses by examining biomarkers such as ctDNA, CTCs, and exosomes derived from body fluids-mainly blood. Its benefits over conventional tissue biopsies, which include reduced risk, faster turnaround times, and the capacity to capture tumor heterogeneity, have established it as an essential instrument in oncology. As precision medicine becomes more integral to cancer treatment, the application of liquid biopsy in the management of solid tumors like lung, breast, colorectal, and prostate cancer is continually growing, further propelling the advancement of this segment.

The market is categorized into four segments based on End-User: Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others. The Hospitals and Laboratories segment is at the forefront of market growth. This segment is driving the expansion of the Liquid Biopsy industry due to the increasing adoption of advanced diagnostic technologies and the growing number of cancer screening and monitoring procedures conducted in these environments. Hospitals and clinical laboratories frequently serve as the initial point of contact for patients undergoing diagnostic assessments, rendering them essential centers for the deployment of liquid biopsy tests. These institutions gain advantages from the presence of skilled professionals, established infrastructure, and access to high-throughput instruments such as NGS and PCR platforms.

Liquid Biopsy Market- Geographical Insights

North America leads in market growth, attributed to robust research and development as well as a solid reimbursement framework. The region's sophisticated healthcare system heightened awareness regarding early cancer screening, and strong partnerships between academic institutions and industry stakeholders further solidify North America's prominent role in the global liquid biopsy market. As reported by the American Medical Association, the United States allocated USD 4,866.5 billion for healthcare in 2023. Europe also orders a substantial portion of the market, bolstered by increasing cancer awareness, enhanced access to healthcare, and government funding for early detection initiatives.

Liquid Biopsy Market- Competitive Landscape:

The liquid biopsy market is characterized by intense competition and constant evolution, with numerous established and new entrants seeking to secure a competitive advantage through innovation, collaborations, and growth strategies. Firms are competing based on cutting-edge technologies such as next-generation sequencing (NGS), droplet digital PCR, and multi-gene panel testing to enhance the sensitivity, specificity, and speed of liquid biopsy assays. Leading companies are placing greater emphasis on emerging markets in the Asia Pacific and Latin America by setting up regional subsidiaries and distribution networks to seize untapped opportunities.

Recent Developments:

On November 1, 2023, Illumina Inc., a worldwide frontrunner in DNA sequencing and array-based technologies, announced the launch of a new generation of its distributed liquid biopsy assay designed for genomic profiling. The latest TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood samples when tissue testing is not feasible, or enhances tissue-based testing.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Guardant Health, Inc.
  • Foundation Medicine, Inc. (Roche subsidiary)
  • Illumina, Inc.
  • GRAIL, Inc. (a subsidiary of Illumina)
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • Freenome Holdings, Inc.
  • QIAGEN N.V.
  • Lucence Diagnostics
  • Inivata Ltd. (NeoGenomics subsidiary)
  • Angle plc
  • Sysmex Corporation
  • Biocept, Inc.
  • Oncocyte Corporation
  • Personal Genome Diagnostics (PGDx)
  • Chronix Biomedical
  • Epic Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Blood Sample
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER- MARKET ANALYSIS, 2019 - 2032

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vehicles (EVs)
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Reproductive Health
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

GLOBAL LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Liquid Biopsy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Liquid Biopsy Market Snippet by Sample Type
    • 2.1.2. Liquid Biopsy Market Snippet by Biomarker
    • 2.1.3. Liquid Biopsy Market Snippet by Technology
    • 2.1.4. Liquid Biopsy Market Snippet by Product
    • 2.1.5. Liquid Biopsy Market Snippet by Clinical Application
    • 2.1.6. Liquid Biopsy Market Snippet by Application
    • 2.1.7. Liquid Biopsy Market Snippet by End-User
    • 2.1.8. Liquid Biopsy Market Snippet by Country
    • 2.1.9. Liquid Biopsy Market Snippet by Region
  • 2.2. Competitive Insights

3. Liquid Biopsy Key Market Trends

  • 3.1. Liquid Biopsy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Liquid Biopsy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Liquid Biopsy Market Opportunities
  • 3.4. Liquid Biopsy Market Future Trends

4. Liquid Biopsy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Liquid Biopsy Market Landscape

  • 6.1. Liquid Biopsy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Liquid Biopsy Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
    • 7.1.2. Blood Sample
    • 7.1.3. Others

8. Liquid Biopsy Market - By Biomarker

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Biomarker, 2024 & 2032 (%)
    • 8.1.2. Circulating Tumor Cells (CTCs)
    • 8.1.3. Circulating Tumor DNA (ctDNA)
    • 8.1.4. Extracellular Vehicles (EVs)
    • 8.1.5. Others

9. Liquid Biopsy Market - By Technology

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 9.1.2. Multi-gene-parallel Analysis (NGS)
    • 9.1.3. Single Gene Analysis (PCR Microarrays)

10. Liquid Biopsy Market - By Product

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Product, 2024 & 2032 (%)
    • 10.1.2. Instruments
    • 10.1.3. Consumables Kits and Reagents
    • 10.1.4. Software and Services

11. Liquid Biopsy Market - By Clinical Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Clinical Application, 2024 & 2032 (%)
    • 11.1.2. Therapy Selection
    • 11.1.3. Treatment Monitoring
    • 11.1.4. Early Cancer Screening
    • 11.1.5. Recurrence Monitoring
    • 11.1.6. Others

12. Liquid Biopsy Market - By Application

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 12.1.2. Cancer
    • 12.1.3. Reproductive Health
    • 12.1.4. Lung Cancer
    • 12.1.5. Prostate Cancer
    • 12.1.6. Breast Cancer
    • 12.1.7. Colorectal Cancer
    • 12.1.8. Leukemia
    • 12.1.9. Gastrointestinal Cancer
    • 12.1.10. Others

13. Liquid Biopsy Market - By End-User

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 13.1.2. Hospitals and Laboratories
    • 13.1.3. Specialty Clinics
    • 13.1.4. Academic and Research Centers
    • 13.1.5. Others

14. Liquid Biopsy Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Liquid Biopsy Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Liquid Biopsy Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Liquid Biopsy Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Liquid Biopsy Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Liquid Biopsy Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Biomarker, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By Clinical Application, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Liquid Biopsy Industry

  • 15.1. Competitive Dashboard
    • 15.1.1. Competitive Benchmarking
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Guardant Health, Inc.
    • 15.2.2. Foundation Medicine, Inc. (Roche subsidiary)
    • 15.2.3. Illumina, Inc.
    • 15.2.4. GRAIL, Inc. (subsidiary of Illumina)
    • 15.2.5. Bio-Rad Laboratories, Inc.
    • 15.2.6. Exact Sciences Corporation
    • 15.2.7. Thermo Fisher Scientific Inc.
    • 15.2.8. Natera, Inc.
    • 15.2.9. Freenome Holdings, Inc.
    • 15.2.10. QIAGEN N.V.
    • 15.2.11. Lucence Diagnostics
    • 15.2.12. Inivata Ltd. (NeoGenomics subsidiary)
    • 15.2.13. Angle plc
    • 15.2.14. Sysmex Corporation
    • 15.2.15. Biocept, Inc.
    • 15.2.16. Oncocyte Corporation
    • 15.2.17. Personal Genome Diagnostics (PGDx)
    • 15.2.18. Chronix Biomedical
    • 15.2.19. Epic Sciences, Inc.
    • 15.2.20. Cynvenio Biosystems, Inc.
    • 15.2.21. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us